Zacks Investment Research downgraded DexCom, Inc. (NASDAQ:DXCM) to Strong Sell in a statement released earlier today.
- Updated: October 4, 2016
Having a price of $84.98, DexCom, Inc. (NASDAQ:DXCM) traded -3.57% lower on the day. With the last close up 5.73% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. DexCom, Inc. has recorded a 50-day average of $91.77 and a two hundred day average of $77.51. Volume of trade was down over the average, with 757,704 shares of DXCM changing hands under the typical 856,514
Zacks Investment Research has downgraded DexCom, Inc. (NASDAQ:DXCM) to Strong Sell in a statement released on 10/04/2016.
On Sunday October 02, 2016, B. Riley released a statement on DexCom, Inc. (NASDAQ:DXCM) upped the target price from $0.00 to $97.00 that suggested an upside of 0.11%.
With a total market value of $0, DexCom, Inc. has with a one year low of $47.92 and a one year high of $96.38 .
More About DexCom, Inc. (NASDAQ:DXCM)
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. It had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system. DexCom SHARE enables users of its G4 PLATINUM System to have their sensor glucose information remotely monitored by their family or friends. The G4 PLATINUM Receiver with Share uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient's receiver and a mobile application on the patient's iPhone to transmit glucose information.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.